| 1 |
obtained by 6-hydroxydopamine
(17 times)
|
Neurology
(7 times)
|
PD (8 times)
DA (5 times)
TH (3 times)
|
1981 Evidence for an interaction of opioid and noradrenergic locus coeruleus systems in the regulation of environmental stimulus-directed behavior.
|
| 2 |
oxidative stress induced by 6-hydroxydopamine
(15 times)
|
Neurology
(4 times)
|
PD (6 times)
GPx (2 times)
MDA (2 times)
|
2002 Effects of (-)-nicotine and (-)-cotinine on 6-hydroxydopamine-induced oxidative stress and neurotoxicity: relevance for Parkinson's disease.
|
| 3 |
6-OH-dopamine
(12 times)
|
Neurology
(4 times)
|
ACh (2 times)
NA (2 times)
PD (2 times)
|
1976 On spinal noradrenaline receptor supersensitivity: correlation between nerve terminal densities and flexor reflexes various times after intracisternal 6-hydroxydopamine.
|
| 4 |
neurotoxin, 6-hydroxy dopamine
(9 times)
|
Neurology
(5 times)
|
DA (2 times)
PD (2 times)
PKD1 (2 times)
|
1988 Dopamine and serotonin in cat retina: electroretinography and histology.
|
| 5 |
H(2)O(2) and 6-hydroxydopamine
(4 times)
|
Neurology
(1 time)
|
HO (1 time)
HON (1 time)
NQO1 (1 time)
|
2006 Ondamtanggamibang protects neurons from oxidative stress with induction of heme oxygenase-1.
|
| 6 |
oxidative neurotoxin 6-hydroxydopamine
(4 times)
|
Pharmacology
(2 times)
|
DA (2 times)
PD (2 times)
FGF (1 time)
|
2006 Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease.
|
| 7 |
Oertel 6-hydroxydopamine
(3 times)
|
Science
(1 time)
|
CMV (1 time)
DAT (1 time)
GI (1 time)
|
1998 Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
|
| 8 |
operation with 6-hydroxydopamine
(3 times)
|
Physiology
(1 time)
|
ACh (1 time)
Ang II (1 time)
BW (1 time)
|
1978 Prevention of compensatory ovarian hypertrophy by local treatment of the ovary with 6-OHDA.
|
| 9 |
oral activity in neonatal 6-hydroxydopamine
(2 times)
|
Neurology
(1 time)
|
DA (2 times)
DOPAC (1 time)
HVA (1 time)
|
1992 Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system.
|
| 10 |
other cats 6-hydroxydopamine
(2 times)
|
Brain
(1 time)
|
AR (1 time)
BP (1 time)
GFAP (1 time)
|
1987 Protection of CGS 10078B against ouabain-induced arrhythmia in the cat.
|
| 11 |
out with either 6-hydroxydopamine
(2 times)
|
Brain
(2 times)
|
5,6-DHT (1 time)
alpha-MPT (1 time)
DMI (1 time)
|
1981 Effect of manipulating central catecholamines on puberty and the surge of luteinizing hormone and gonadotropin releasing hormone induced by pregnant mare serum gonadotropin in female rats.
|
| 12 |
toxin 6-hydroxy dopamine
(2 times)
|
Neurology
(2 times)
|
DA (1 time)
GFP (1 time)
KA (1 time)
|
2006 A method for a more complete in vitro Parkinson's model: slice culture bioassay for modeling maintenance and repair of the nigrostriatal circuit.
|
| 13 |
(5-HT) or with 6-hydroxydopamine
(1 time)
|
Pharmacology
(1 time)
|
5-HT (1 time)
NA (1 time)
|
1979 Alcohol intake, ethanol-induced narcosis and intoxication in rats following neonatal 6-hydroxydopamine or 5, 7-dihydroxytryptamine treatment.
|
| 14 |
14-month-old rats pretreated with either 6-hydroxydopamine
(1 time)
|
Geriatrics
(1 time)
|
NTS (1 time)
|
1993 Age-related reduction of reflex bradycardia in conscious rats by catecholaminergic nucleus tractus solitarius lesions.
|
| 15 |
17beta-oestradiol in defending dopaminergic neurones against 6-hydroxydopamine
(1 time)
|
Endocrinology
(1 time)
|
GDNF (1 time)
PD (1 time)
SN (1 time)
|
2012 GDNF contributes to oestrogen-mediated protection of midbrain dopaminergic neurones.
|
| 16 |
8-OH-DPAT were attenuated by i.v. and intra-adrenal treatment with 6-hydroxydopamine
(1 time)
|
Drug Therapy
(1 time)
|
8-OH-DPAT (1 time)
|
1994 Central stimulation of adrenocortical secretion by 5-hydroxytryptamine1A agonists is mediated by sympathomedullary activation.
|
| 17 |
anti-oxidative properties in 6-hydroxydopamine
(1 time)
|
Neurosciences
(1 time)
|
DCFH-DA (1 time)
GCLM (1 time)
HO-1 (1 time)
|
2018 Simvastatin Inhibits Activation of NADPH Oxidase/p38 MAPK Pathway and Enhances Expression of Antioxidant Protein in Parkinson Disease Models.
|
| 18 |
control, 6-hydroxy-dopamine
(1 time)
|
Pharmacology
(1 time)
|
CAR (1 time)
|
1979 Effects of pretreatment with 6-hydroxydopamine or noradrenergic receptor blockers on the clonidine-induced distruption of conditioned avoidance responding.
|
| 19 |
group have demonstrated that hesperidin has neuroprotective effect in 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
DA (1 time)
DOPAC (1 time)
HVA (1 time)
|
2020 Hesperidin protects against behavioral alterations and loss of dopaminergic neurons in 6-OHDA-lesioned mice: the role of mitochondrial dysfunction and apoptosis.
|
| 20 |
HCQ on the 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
GPx (1 time)
HCQ (1 time)
PD (1 time)
|
2022 Hydroxychloroquine attenuated motor impairment and oxidative stress in a rat 6-hydroxydopamine model of Parkinson's disease.
|
| 21 |
hemisphere or bilateral intrastriatal 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
ICMS (1 time)
SNc (1 time)
|
2009 Neocortical movement representations are reduced and reorganized following bilateral intrastriatal 6-hydroxydopamine infusion and dopamine type-2 receptor antagonism.
|
| 22 |
hemispheres of 6-hydroxydopamine
(1 time)
|
Antioxidants
(1 time)
|
FRET (1 time)
|
2021 Characterization of the Striatal Extracellular Matrix in a Mouse Model of Parkinson's Disease.
|
| 23 |
hemispheres of unilaterally 6-hydroxydopamine
(1 time)
|
Chemistry Techniques, Analytical
(1 time)
|
Dyn A (1 time)
|
2005 Altered extracellular striatal in vivo biotransformation of the opioid neuropeptide dynorphin A(1-17) in the unilateral 6-OHDA rat model of Parkinson's disease.
|
| 24 |
HIPP of sham-lesioned and 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
HIPP (1 time)
l-DOPA (1 time)
PD (1 time)
|
2010 High-frequency stimulation of the subthalamic nucleus and L-3,4-dihydroxyphenylalanine inhibit in vivo serotonin release in the prefrontal cortex and hippocampus in a rat model of Parkinson's disease.
|
| 25 |
hippocampus of 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
PD (1 time)
VGSCs (1 time)
|
2019 Voltage-Gated Sodium Channels Are Involved in Cognitive Impairments in Parkinson's Disease- like Rats.
|
| 26 |
homogenates of control and 6-hydroxydopamine
(1 time)
|
Biochemistry
(1 time)
|
DHA (1 time)
NE (1 time)
QNB (1 time)
|
1982 Characterization of postsynaptic beta-adrenergic receptors and presynaptic muscarinic cholinergic receptors in the rat spleen.
|
| 27 |
homolog of eEF1A1/eEF1A2, on 6-hydroxydopamine
(1 time)
|
Neurosciences
(1 time)
|
DA (1 time)
mTOR (1 time)
PD (1 time)
|
2020 Downregulation of eEF1A/EFT3-4 Enhances Dopaminergic Neurodegeneration After 6-OHDA Exposure in C. elegans Model.
|
| 28 |
hyperlocomotion of neonatal 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
ADHD (1 time)
DA (1 time)
|
1994 Proposed animal model of attention deficit hyperactivity disorder.
|
| 29 |
hyperoside on 6-hydroxydopamine
(1 time)
|
Chemistry
(1 time)
|
HO-1 (1 time)
Nrf2 (1 time)
ROS (1 time)
|
2019 Suppression of 6-Hydroxydopamine-Induced Oxidative Stress by Hyperoside Via Activation of Nrf2/HO-1 Signaling in Dopaminergic Neurons.
|
| 30 |
metabolic homeostasis due to 6-hydroxydopamine
(1 time)
|
Neurosciences
(1 time)
|
GC (1 time)
PD (1 time)
|
2019 Glucose Homeostasis Is Not Affected in a Murine Model of Parkinson's Disease Induced by 6-OHDA.
|
| 31 |
neonatal 6-hydroxy-dopamine
(1 time)
|
Neurology
(1 time)
|
ADHD (1 time)
|
2011 Caffeine improves attention deficit in neonatal 6-OHDA lesioned rats, an animal model of attention deficit hyperactivity disorder (ADHD).
|
| 32 |
neurons had degenerated following an intranigral injection of 6-hydroxydopamine
(1 time)
|
Pharmacology
(1 time)
|
CDP (1 time)
DA (1 time)
|
1981 Effects of CDP-choline on striatal dopamine level and behavior in rats.
|
| 33 |
OBJECTIVE: 6-hydroxy dopamine
(1 time)
|
Inflammation
(1 time)
|
CMN (1 time)
PP (1 time)
|
2016 Neuroprotective potential of curcumin in combination with piperine against 6-hydroxy dopamine induced motor deficit and neurochemical alterations in rats.
|
| 34 |
OBJECTIVE: To explore the possibility that the neurotoxin, 6-hydroxydopamine
(1 time)
|
Allergy and Immunology
(1 time)
|
IgG (1 time)
PD (1 time)
SN (1 time)
|
2015 6-Hydroxydopamine as a tool to understand adaptive immune system-induced dopamine neurodegeneration in Parkinson's disease.
|
| 35 |
observed after PC12 cell-containing capsules were implanted into unilaterally 6-hydroxydopamine
(1 time)
|
Cell Biology
(1 time)
|
CNS (1 time)
DA (1 time)
|
1992 Polymer-encapsulated PC12 cells: long-term survival and associated reduction in lesion-induced rotational behavior.
|
| 36 |
observed autophagic vacuoles and lysosomes were accumulated in the 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
3-MA (1 time)
PD (1 time)
|
2010 Parkinson's disease involves autophagy and abnormal distribution of cathepsin L.
|
| 37 |
observed in animals unilaterally infused with 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
---
|
2007 Unilateral implantation of dopamine-loaded biodegradable hydrogel in the striatum attenuates motor abnormalities in the 6-hydroxydopamine model of hemi-parkinsonism.
|
| 38 |
observed in maternal rats following dopamine-depleting 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
---
|
1994 Maternal behavior of female rats with 6-OHDA lesions in the ventral striatum: characterization of the pup retrieval deficit.
|
| 39 |
observed in neonatal rats given 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
5-HIAA (1 time)
DBH (1 time)
NE (1 time)
|
1994 Heterotypic sprouting of serotonergic forebrain fibers in the brindled mottled mutant mouse.
|
| 40 |
observed in previous studies that 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
IR (2 times)
DA (1 time)
TH (1 time)
|
2009 Involvement of astroglial fibroblast growth factor-2 and microglia in the nigral 6-OHDA parkinsonism and a possible role of glucocorticoid hormone on the glial mediated local trophism and wound repair.
|
| 41 |
observed in the rats with additional 6-hydroxydopamine
(1 time)
|
Psychopharmacology
(1 time)
|
5-MeODMT (1 time)
alpha-MT (1 time)
DRN (1 time)
|
1982 Possible mechanism of 5-methoxy-N,N-dimethyltryptamine-induced turning behaviour in DRN lesioned rats.
|
| 42 |
observed in the SNC following treatment with the neurotoxin 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
CB (1 time)
CR (1 time)
DAergic (1 time)
|
2001 GFRalpha-1 mRNA in dopaminergic and nondopaminergic neurons in the substantia nigra and ventral tegmental area.
|
| 43 |
observed with and without pretreatment by 6-hydroxydopamine
(1 time)
|
Occupational Medicine
(1 time)
|
DA (1 time)
DBH (1 time)
NE (1 time)
|
1985 [The response of monoamines in the rat brain to local vibration exposure].
|
| 44 |
obtained from animals given 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
LTP (1 time)
TRH (1 time)
|
1991 Effects of thyrotropin-releasing hormone and a related analog, CNK-602A, on long-term potentiation in the mossy fiber-CA3 pathway of guinea pig hippocampal slices.
|
| 45 |
obtained ipsilateral and contralateral to 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
---
|
1993 Electrophysiological characterization of rat striatal neurons in vitro following a unilateral lesion of dopamine cells.
|
| 46 |
obtained with benextramine in femoral arteries acutely denervated with 6-hydroxydopamine
(1 time)
|
Cardiology
(1 time)
|
CRC (1 time)
|
1996 Serotonin-induced vasoconstriction in rabbit femoral artery: mediation by both 5-HT2 serotonergic and alpha 1-adrenoceptors.
|
| 47 |
obtained with intraventricular 6-hydroxydopamine
(1 time)
|
Psychopharmacology
(1 time)
|
DA (1 time)
|
1976 Decreased intracranial self-stimulation after neuroleptics or 6-hydroxydopamine: evidence for mediation by motor deficits rather than by reduced reward.
|
| 48 |
occlusal disharmony in rats injected with 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
CRH (1 time)
HPA (1 time)
NA (1 time)
|
2011 Lesions of the ventral ascending noradrenergic bundles decrease the stress response to occlusal disharmony in rats.
|
| 49 |
occurred in a concentration-dependent manner after exposure to 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
---
|
2007 Rapid activation of ERK by 6-hydroxydopamine promotes survival of dopaminergic cells.
|
| 50 |
occurred in chronic ANH rats following chemical sympathectomy with 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
ANH (1 time)
MDH (1 time)
NA (1 time)
|
1991 Adjacent neuropathic hyperalgesia in rats: a model for sympathetic independent pain.
|
| 51 |
OECs to the neurotoxin 6-hydroxydopamine
(1 time)
|
Stem Cells
(1 time)
|
CNS (1 time)
GFs (1 time)
OECs (1 time)
|
2015 Phenotypic Modulation and Neuroprotective Effects of Olfactory Ensheathing Cells: a Promising Tool for Cell Therapy.
|
| 52 |
officinalis, for alleviating the motor deficits induced by 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
PD (1 time)
TH (1 time)
|
2011 Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
|
| 53 |
oil for 50 days and subjected to unilateral intrastriatal 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
iNOS (1 time)
NO (1 time)
PD (1 time)
|
2017 Neuroprotective effect of omega-3 polyunsaturated fatty acids in the 6-OHDA model of Parkinson's disease is mediated by a reduction of inducible nitric oxide synthase.
|
| 54 |
olfactory bulb, both in healthy and in a 6-hydroxydopamine
(1 time)
|
Pharmacology
(1 time)
|
miR-124 (1 time)
NPs (1 time)
PD (1 time)
|
2016 MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson's disease.
|
| 55 |
olfactory tubercle had been produced by 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
3MT-HVA (1 time)
DA (1 time)
|
1990 Acetorphan, an Enkephalinase Inhibitor, Modulates Dopaminergic Transmission in Rat Olfactory Tubercle, but not in the Nucleus Accumbens and Striatum.
|
| 56 |
oligos ameliorated the motor symptoms in the 6-hydroxydopamine
(1 time)
|
Cell Biology
(1 time)
|
NR1 (1 time)
NR2B (1 time)
PD (1 time)
|
2012 Small interfering RNA specific for N-methyl-D-aspartate receptor 2B offers neuroprotection to dopamine neurons through activation of MAP kinase.
|
| 57 |
Once stable responding was achieved with this schedule, bilateral 6-hydroxydopamine
(1 time)
|
Psychopharmacology
(1 time)
|
BP (1 time)
DA (1 time)
DOPAC (1 time)
|
1996 Effect of 6-hydroxydopamine lesions of the medial prefrontal cortex on intravenous cocaine self-administration under a progressive ratio schedule of reinforcement.
|
| 58 |
ondansetron alleviates dyskinesia in the 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
AIMs (1 time)
L-DOPA (1 time)
|
2021 Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat.
|
| 59 |
one day following treatment with 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
---
|
1984 Sympathetic control of sexual reflexes: peripheral 6-hydroxydopamine administration facilitates the onset of penile reflexes in male rats.
|
| 60 |
one given lesioning with 6-hydroxydopamine
(1 time)
|
General Surgery
(1 time)
|
ABC (1 time)
ANS (1 time)
CNS (1 time)
|
1998 Asymmetry of sympathetic activity in a rat model of Parkinson's disease induced by 6-hydroxydopamine: haemodynamic, electrocardiographic and biochemical changes.
|
| 61 |
one procedure, rats were stereotaxically injected with 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
NADPH-d (1 time)
NO (1 time)
NOS (1 time)
|
2003 Effects of electrolytic and 6-hydroxydopamine lesions of rat nigrostriatal pathway on nitric oxide synthase and nicotinamide adenine dinucleotide phosphate diaphorase.
|
| 62 |
One such factor is 6-hydroxydopamine
(1 time)
|
Metabolism
(1 time)
|
PD (1 time)
|
2007 Cell stress induced by the parkinsonian mimetic, 6-hydroxydopamine, is concurrent with oxidation of the chaperone, ERp57, and aggresome formation.
|
| 63 |
one such input - the superior colliculus - in 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
---
|
2013 Enhanced visual responses in the superior colliculus and subthalamic nucleus in an animal model of Parkinson's disease.
|
| 64 |
one suprasylvian cortex to 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
HPLC (1 time)
|
1985 Visual discrimination learning and interhemispheric transfer in the cat, as affected by 6-hydroxydopamine.
|
| 65 |
One week following gene delivery, the neurotoxin 6-hydroxydopamine
(1 time)
|
Pharmacology
(1 time)
|
DA (1 time)
GDNF (1 time)
SN (1 time)
|
2001 Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat.
|
| 66 |
One week following two bilateral 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
DA (1 time)
mPFC (1 time)
NAc (1 time)
|
1999 Dopamine depletion in the medial prefrontal cortex induces sensitized-like behavioral and neurochemical responses to cocaine.
|
| 67 |
one week later, 6-hydroxydopamine
(1 time)
|
Molecular Biology
(1 time)
|
CDNF (1 time)
CDNF-BMSCs (1 time)
DA (1 time)
|
2014 Effects of engineered conserved dopamine neurotrophic factor-expressing bone marrow stromal cells on dopaminergic neurons following 6-OHDA administrations.
|
| 68 |
only dopaminergic deficiency with 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
---
|
2004 Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
|
| 69 |
operant behavior in mice, mice with 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
---
|
2010 Lever pressing responses under a fixed-ratio schedule of mice with 6-hydroxydopamine-induced dopamine depletion in the nucleus accumbens.
|
| 70 |
opiate receptor antagonist naloxone and the neurotoxic drug 6-hydroxydopamine
(1 time)
|
Reproductive Medicine
(1 time)
|
---
|
1989 Effect of simultaneous local injection of 6-hydroxydopamine and naloxone on the testis of neonatal rats.
|
| 71 |
optic nerve and complete 6-hydroxydopamine
(1 time)
|
Genetics, Medical
(1 time)
|
GDNF (1 time)
|
2006 Potentiation of in vivo neuroprotection by BclX(L) and GDNF co-expression depends on post-lesion time in deafferentiated CNS neurons.
|
| 72 |
optimized cell culture protocol prior to intrastriatal transplantation into 6-hydroxydopamine
(1 time)
|
Cell Biology
(1 time)
|
BDNF (1 time)
DA (1 time)
EGFP (1 time)
|
2011 The colayer method as an efficient way to genetically modify mesencephalic progenitor cells transplanted into 6-OHDA rat model of Parkinson's disease.
|
| 73 |
optogenetic STN DBS in female rats following unilateral 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
ChR2 (1 time)
DBS (1 time)
GPe (1 time)
|
2020 Frequency-Specific Optogenetic Deep Brain Stimulation of Subthalamic Nucleus Improves Parkinsonian Motor Behaviors.
|
| 74 |
or, as a control, with the toxin 6-hydroxydopamine
(1 time)
|
Physiological Phenomena
(1 time)
|
AMPA (1 time)
AP (1 time)
HR (1 time)
|
2017 Reduced responses to glutamate receptor agonists follow loss of astrocytes and astroglial glutamate markers in the nucleus tractus solitarii.
|
| 75 |
orally as a pre-treatment prior to 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
EGCG (1 time)
|
2009 Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection.
|
| 76 |
order to determine whether unilateral 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
Acb (1 time)
TH (1 time)
|
1996 Altered Fos-like immunoreactivity in terminal regions of the mesotelencephalic dopamine system is associated with reappearance of tyrosine hydroxylase immunoreactivity at the sites of focal 6-hydroxydopamine lesions in the nucleus accumbens.
|
| 77 |
orexin-A neuroprotection in 6-hydroxydopamine
(1 time)
|
Geriatrics
(1 time)
|
COX-2 (1 time)
MTT (1 time)
Nrf2 (1 time)
|
2016 Orexin-A Protects Human Neuroblastoma SH-SY5Y Cells Against 6-Hydroxydopamine-Induced Neurotoxicity: Involvement of PKC and PI3K Signaling Pathways.
|
| 78 |
ORG 31433 accelerated functional recovery from 6-hydroxydopamine
(1 time)
|
Biochemistry
(1 time)
|
---
|
1991 Structural modifications of the ACTH-(4-9) analog ORG 2766 yields peptides with high biological activity.
|
| 79 |
organoids treated with the neurotoxic compound 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
PD (1 time)
|
2020 Machine learning-assisted neurotoxicity prediction in human midbrain organoids.
|
| 80 |
organotypic ex vivo slices: axotomy, rotenone, and 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
GDNF (1 time)
PD (1 time)
SN (1 time)
|
2019 Therapeutic efficacy of glial cell-derived neurotrophic factor loaded collagen scaffolds in ex vivo organotypic brain slice Parkinson's disease models.
|
| 81 |
organs are selectively destroyed by 6-hydroxydopamine
(1 time)
|
General Surgery
(1 time)
|
---
|
1979 Gastric acid secretion after chemical sympathectomy.
|
| 82 |
OS injury in 6-hydroxydopamine
(1 time)
|
Biochemistry
(1 time)
|
GSH-Px (1 time)
GSK-3beta-Ser9 (1 time)
MDA (1 time)
|
2018 Salidroside Protection Against Oxidative Stress Injury Through the Wnt/beta-Catenin Signaling Pathway in Rats with Parkinson's Disease.
|
| 83 |
osmotic minipumps to continuously deliver the neurotoxin 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
---
|
1984 The stability of 6-hydroxydopamine under minipump conditions.
|
| 84 |
ostreatus was treated against a dopaminergic neurotoxin, 6-hydroxydopamine
(1 time)
|
Biochemistry
(1 time)
|
PD (1 time)
PINK1 (1 time)
|
2019 Anthraquinone from Edible Fungi Pleurotus ostreatus Protects Human SH-SY5Y Neuroblastoma Cells Against 6-Hydroxydopamine-Induced Cell Death-Preclinical Validation of Gene Knockout Possibilities of PARK7, PINK1, and SNCA1 Using CRISPR SpCas9.
|
| 85 |
other DA metabolites, both in intact and in 6-hydroxydopamine
(1 time)
|
Brain
(1 time)
|
DA (1 time)
DOPALD (1 time)
MAO (1 time)
|
2000 Modulation of dihydroxyphenylacetaldehyde extracellular levels in vivo in the rat striatum after different kinds of pharmacological treatment.
|
| 86 |
other hand, 6-hidroxidopamine
(1 time)
|
Chemistry, Pharmaceutical
(1 time)
|
TFS (1 time)
|
2021 Transcranial Focal Electrical Stimulation Modifies Biogenic Amines' Alterations Induced by 6-Hydroxydopamine in Rat Brain.
|
| 87 |
other hand, tissues treated with 6-hydroxydopamine
(1 time)
|
Drug Therapy
(1 time)
|
---
|
1981 Further studies on the mechanism of action of methyldopa on the vas deferens of the guinea-pig.
|
| 88 |
other neurotoxins like 6-hydroxydopamine
(1 time)
|
Pharmacology
(1 time)
|
MPTP (1 time)
|
2021 Chemically induced models of Parkinson's disease.
|
| 89 |
other rats injected with 6-hydroxydopamine hydrochloride
(1 time)
|
Veterinary Medicine
(1 time)
|
AVP (1 time)
|
1999 Model of emotional stress in rats.
|
| 90 |
out in unilateral 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
Ipt (1 time)
PD (1 time)
|
2005 Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
|
| 91 |
Outgrowth and Attenuates 6-Hydroxydopamine
(1 time)
|
Nervous System
(1 time)
|
HO-1 (1 time)
Keap1 (1 time)
NGF (1 time)
|
2015 N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway.
|
| 92 |
outgrowth but also attenuated 6-hydroxydopamine
(1 time)
|
Nervous System
(1 time)
|
HO-1 (1 time)
Keap1 (1 time)
NGF (1 time)
|
2015 N-Propargyl Caffeate Amide (PACA) Potentiates Nerve Growth Factor (NGF)-Induced Neurite Outgrowth and Attenuates 6-Hydroxydopamine (6-OHDA)-Induced Toxicity by Activating the Nrf2/HO-1 Pathway.
|
| 93 |
ovariectomized 6-hydroxydopamine
(1 time)
|
|
AIMs (1 time)
L-dopa (1 time)
LID (1 time)
|
2022 Modulation by Estradiol of L-Dopa-Induced Dyskinesia in a Rat Model of Post-Menopausal Hemiparkinsonism.
|
| 94 |
ovariectomized, estrogen-primed rats, 6-hydroxydopamine
(1 time)
|
Endocrinology
(1 time)
|
VNAT (1 time)
|
1977 Effect of lesions in the ventral noradrenergic tract produced by microinjection of 6-hydroxydopamine on gonadotropin release in the rat.
|
| 95 |
over 11 days in rats with unilateral 6-hydroxydopamine
(1 time)
|
Behavioral Sciences
(1 time)
|
3-OMD (1 time)
COMT (1 time)
|
1994 3-O-methyl-DOPA is not involved in the development of behavioral supersensitivity after repeated L-dopa administration in 6-OHDA lesioned rats.
|
| 96 |
over the newborn rat cerebellum by 6-hydroxydopamine
(1 time)
|
Biology
(1 time)
|
---
|
1985 Meningeal cells are involved in foliation, lamination, and neurogenesis of the cerebellum: evidence from 6-hydroxydopamine-induced destruction of meningeal cells.
|
| 97 |
overexpression and 6-hydroxydopamine
(1 time)
|
Neurology
(1 time)
|
DA (1 time)
hVPS41 (1 time)
PD (1 time)
|
2009 VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease.
|
| 98 |
oxidants such as hydrogen peroxide and 6-hydroxydopamine
(1 time)
|
Cell Biology
(1 time)
|
BFA (1 time)
DBM (1 time)
ER (1 time)
|
2007 A dibenzoylmethane derivative protects dopaminergic neurons against both oxidative stress and endoplasmic reticulum stress.
|
| 99 |
oxidation product, 6-hydroxydopamine
(1 time)
|
Chemistry
(1 time)
|
MPTP (1 time)
PD (1 time)
|
2009 L-DOPA-induced 6-hydroxydopamine production in the striata of rodents is sensitive to the degree of denervation.
|
| 100 |
oxidative assault by 6-hydroxydopamine
(1 time)
|
Nervous System
(1 time)
|
GA (1 time)
GCLC (1 time)
Keap1 (1 time)
|
2021 Ginnalin A Binds to the Subpockets of Keap1 Kelch Domain To Activate the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells.
|
A Search Service for Abbreviation / Long Form